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AbstrAct
ObjeCtive
To determine whether the immunogenicity of a single 
dose infant priming schedule of serogroup C 
meningococcal (MenC) conjugate vaccine is non-
inferior to a two dose priming schedule when followed 
by a booster dose at age 12 months.
Design
Phase IV open label randomised controlled trial carried 
out from July 2010 until August 2013
setting
Four centres in the United Kingdom and one centre in 
Malta.
PartiCiPants
Healthy infants aged 6–12 weeks followed up until age 
24 months.
interventiOns
In the priming phase of the trial 509 infants were 
randomised in a 10:10:7:4 ratio into four groups to 
receive either a single MenC-cross reacting material 
197 (CRM) dose at 3 months; two doses of MenC-CRM 
at 3 and 4 months; a single MenC-polysaccharide-
tetanus toxoid (TT) dose at 3 months; or no MenC 
doses, respectively. Haemophilus influenzae type b 
(Hib)-MenC-TT vaccine was administered to all infants 
at 12 months of age. All infants also received the 
nationally routinely recommended vaccines. Blood 
samples were taken at age 5, 12, 13, and 24 months.
Main OutCOMe Measure
MenC serum bactericidal antibody assay with rabbit 
complement (rSBA) one month after the Hib-MenC-TT 
vaccine. Non-inferiority was met if the lower 95% 
confidence limit of the difference in the mean log10 
MenC rSBA between the single dose MenC-CRM and 
the two dose MenC-CRM groups was >−0.35.
results
The primary objective was met: after a Hib-MenC-TT 
booster dose at 12 months of age the MenC rSBA 
geometric mean titres induced in infants primed with a 
single MenC-CRM dose were not inferior to those 
induced in participants primed with two MenC-CRM 
doses in infancy (660 (95% confidence interval 498 to 
876) v 295 (220 to 398)) with a corresponding 
difference in the mean log10 MenC rSBA of 0.35 (0.17 to 
0.53) that showed superiority of the single over the two 
dose schedule). Exploration of differences between 
the priming schedules showed that one month after 
Hib-MenC-TT vaccination, MenC rSBA ≥1:8 was 
observed in >96% of participants previously primed 
with any of the MenC vaccine schedules in infancy and 
in 83% of those who were not vaccinated against MenC 
in infancy. The MenC rSBA geometric mean titres 
induced by the Hib-MenC-TT boost were significantly 
higher in children who were primed with one rather 
than two MenC-CRM doses in infancy. Only priming 
with MenC-TT, however, induced robust MenC 
bactericidal antibody after the Hib-MenC-TT booster 
that persisted until 24 months of age.
COnClusiOns
MenC vaccination programmes with two MenC infant 
priming doses could be reduced to a single priming 
dose without reducing post-boost antibody titres. 
When followed by a Hib-MenC-TT booster dose, infant 
priming with a single MenC-TT vaccine dose induces a 
more robust antibody response than one or two infant 
doses of MenC-CRM. Bactericidal antibody induced by 
a single Hib-MenC-TT conjugate vaccine dose at 12 
months of age (that is, a toddler only schedule), 
without infant priming, is not well sustained at 24 
months. Because of rapid waning of MenC antibody, 
programmes using toddler only schedules will still 
need to rely on herd protection to protect infants and 
young children.
trial registratiOn
Eudract No: 2009-016579-31; NCT01129518; study ID: 
2008_06 (http://clinicaltrials.gov).
Introduction
Control of invasive meningococcal C (MenC) disease 
has been achieved in the United Kingdom, the Nether-
lands, Canada, and Australia, where MenC conjugate 
vaccines have been introduced in the routine national 
childhood immunisation programmes.1 Three licensed 
WhAt Is AlreAdy knoWn on thIs topIc
Different prime and boost schedules for MenC glycoconjugate vaccines are effective 
in controlling MenC disease
Infant protection induced by a single MenC glycoconjugate vaccine dose at 2 or 3 
months of age is similar to that induced by two or three doses
WhAt thIs study Adds
Increasing the number of MenC-CRM doses in infancy reduces the subsequent 
immune response to a MenC glycoconjugate booster
When boosting with Hib-MenC-TT vaccine, priming with a single MenC-TT dose in 
infancy, rather than MenC-CRM, induces more robust bactericidal antibodies that 
are still persistent at 24 months of age
Protection provided by just one MenC glycoconjugate dose at 12 months of age is 
not sustained and will rely on herd immunity
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meningococcal conjugate vaccines are in use: two 
MenC polysaccharide protein conjugate preparations 
utilising the cross reacting material 197 (MenC-CRM), a 
non-toxic mutant of diphtheria toxoid (Menjugate, 
Novartis Vaccines and Diagnostics, Siena, Italy; and 
Meningitec, currently marketed by Nuron Biotech, 
Schaffhausen, Switzerland), and one MenC polysac-
charide-tetanus toxoid (MenC-TT) formulation (Neis-
Vac-C; currently marketed by Pfizer, New York). The 
impact of MenC vaccination was evident within a few 
years, despite differences between countries in MenC 
vaccination schedules, which include whether or not 
an infant “priming” dose is used, the number of these 
priming doses, and whether to accompany introduc-
tion with a mass catch up MenC immunisation cam-
paign for older age groups.2
Starting in 1999 the UK was the first country to launch 
routine MenC conjugate vaccination for all infants con-
currently with staggered catch-up vaccination of indi-
viduals aged 1–25 years up until 2002.3 Since then the 
MenC schedule has been changed twice. In 2006, the 
original three dose MenC infant priming schedule 
administered at 2, 3, and 4 months of age was reduced to 
a 3 and 4 month schedule with the addition of a Hib-
MenC-TT boost at 12 months of age.3 This decision was 
based on results of clinical trials that showed that the 
serological threshold of MenC serum bactericidal anti-
body assay with rabbit complement (rSBA) of ≥1:8, 
accepted to be protective against invasive meningococ-
cal disease,4 was observed in >98% of vaccinated chil-
dren after two infant MenC priming doses5 6 and on 
estimates of rapid waning of MenC vaccine effectiveness 
after infant vaccination.7 Subsequently in 2013, MenC 
infant priming was further reduced to a single dose at 3 
months, with retention of the 12 month old booster and 
the introduction of another booster dose at age 13–14 
years to sustain MenC immunity through adolescence.8
The rationale for a single MenC conjugate vaccine 
dose in infancy is based on limited data from studies 
that looked at the immunogenicity after the first9 10 or a 
single priming MenC vaccine dose at 2 months of age,11 
or the effect a single priming dose of different MenC 
 glycoconjugate formulations had on the immunogenic-
ity of a Hib-MenC-TT booster dose administered to chil-
dren aged 12 months.12 No randomised controlled 
studies have directly compared the effect on the immu-
nogenicity of a Hib-MenC-TT booster after different 
reduced MenC infant immunisation schedules. We 
investigated such differences and assessed the corre-
sponding persistence of MenC bactericidal antibody at 
24 months of age.
Methods
Participants and recruitment
We enrolled 509 healthy infants, born at 37–42 weeks’ 
gestation and aged between 6–12 weeks, in a phase IV 
open labelled randomised controlled trial carried out 
between 5 July 2010 and 1 August 2013 in four centres in 
the UK (Oxford, Bristol, London, and Southampton) 
and one centre in Malta. An invitation letter was sent to 
the parents of all children due for their routine immuni-
sations, and parents who expressed an interest for their 
child to participate in the study were called to ensure 
eligibility. Eligible infants were then asked to visit Mater 
Dei Hospital in Malta or were seen in their homes in the 
UK. The study was divided into three phases: the pri-
mary vaccination phase (from 2–5 months of age); the 
booster phase (from 12–13 months of age), and the per-
sistence phase (at 24 months of age).
Exclusion criteria included known immunosuppres-
sion, a family history of immunodeficiency, administra-
tion of blood products, previous vaccination (except 
with the BCG, hepatitis B, and rotavirus vaccines for the 
primary phase, and with the combined diphtheria, 
 tetanus, acellular pertussis, inactivated polio, and 
 Haemophilus influenzae type b (DTaP-IPV-Hib), and the 
13 valent pneumococcal conjugate vaccines used in the 
primary phase as well as the hepatitis A, influenza, and 
varicella-zoster vaccines for the booster phase), previ-
ous infection with MenC, allergic reactions to any vac-
cine components, a history of seizures or any 
neurological disorder, and severe acute/chronic illness 
at the time of enrolment.
visits and vaccines
Participants were randomised in a 10:10:7:4 ratio into 
four different groups: a single infant dose MenC-CRM 
group, a two infant dose MenC-CRM group, a single 
infant dose MenC-TT group, and a control group (no 
infant MenC vaccine), respectively (table 1). Infants in 
the MenC-CRM groups were immunised with a MenC-
CRM conjugate vaccine (Menjugate) at age 3 months or at 
3 and 4 months. Those in the single infant dose MenC-TT 
group received one dose of the MenC-TT vaccine 
table 1 | timelines of vaccination and blood sampling with different infant meningococcal C (MenC) vaccination schedules
study group
randomisation  
ratio
Phase
Persistence at 
24 months
Primary booster
2 3 4 5 12 13
Single infant dose menC-CRm group 10 — menC-CRm — —
Hib-menC-TT
— —
Two infant dose menC-CRm group 10 — menC-CRm menC-CRm — — —
Control group 4 — — — — — —
Single infant dose menC-TT group 7 — menC-TT — — — —
Routine vaccines all groups — DTaP-IPV-
Hib, PCV13
DTaP-IPV-Hib DTaP-IPV-
Hib, PCV13
— PCV13 mmR —
blood sampling — — — — ✓ ✓ ✓ ✓
menC-CRm (menjugate); menC-TT (NeisVac-C); Hib-menC-TT (menitorix); DTaP-IPV-Hib (Pediacel); PCV13 (Prevenar 13); CRm=cross reacting material 197; TT=tetanus toxoid; Hib=Haemophilus 
influenzae type b.
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(NeisVac-C) at 3 months of age, while infants in the con-
trol group did not receive any MenC vaccine priming 
doses. All infants were vaccinated with a combined 
DTaP-IPV-Hib vaccine (Pediacel, Sanofi Pasteur MSD, 
Lyon, France) at 2, 3, and 4 months of age and with the 13 
valent pneumococcal conjugate vaccine (PCV13, Preve-
nar 13, Pfizer, New York) at 2 and 4 months of age. In the 
booster phase, infants in all groups were vaccinated with 
the Hib-MenC-TT vaccine (Menitorix, GlaxoSmithKline 
Biologicals, Rixensart, Belgium) as well as the routine 
PCV13 vaccine at 12 months of age. All infants received 
the combined measles, mumps, and rubella (MMR) vac-
cine at 13 months. Blood samples were obtained for sero-
logic assays at 5, 12, 13, and 24 months of age (table 1).
Participants in each study site were randomised 
according to a computer generated list produced by the 
Oxford Vaccine Group in Oxford. Stata version 10.0 was 
used to generate the randomisation codes with per-
muted block size of 30 and stratification by centre. 
 Allocation concealment until the point of enrolment 
was achieved through the use of opaque sealed enve-
lopes. Study staff and parents of participants were not 
masked to group allocation after enrolment.
serologic assays
Meningococcal serogroup C antibody was measured as 
described by Maslanka and colleagues13 using a MenC 
rSBA targeting the Neisseria meningitidis C11 
(C:16:P1.7–1,1) strain and baby rabbit serum as the com-
plement source (Pel-Freeze Incorporated, Rodgerson, 
AZ). MenC rSBA titres were expressed as the reciprocal 
of the final serum dilution giving ≥50% killing at 60 
minutes. An rSBA threshold of ≥1:8 was taken as indic-
ative of protection.4 A threshold of ≥1:128 was also 
included as a more conservative protective threshold.14 
MenC rSBA assays were carried out at the Vaccine 
 Evaluation Unit, Public Health England, Manchester 
Laboratory, Manchester Royal Infirmary, Manchester, UK.
safety evaluation
After each immunisation, vaccinated infants were 
observed for 15 minutes for any immediate reactions. 
Parents completed a diary card for five days from the 
day of immunisation and recorded all local and sys-
temic adverse events. Any solicited or unsolicited 
adverse events as well as serious adverse events occur-
ring from the day of vaccination to the subsequent visit 
were noted.
statistical analysis
Our primary objective was to show non-inferiority of the 
MenC geometric mean titres one month after the 12 month 
dose of the Hib-MenC-TT vaccine between the single 
infant dose MenC-CRM and the two infant dose MenC-
CRM groups. The geometric mean titre expresses the 
mean (calculated on log transformed data) back in the 
original units and gives a meaningful expression of cen-
tral tendency of the antibody response in a study popula-
tion. Geometric mean titres (and their 95% confidence 
intervals) were calculated by taking the antilog of the 
mean (and 95% confidence interval) log10 transformed 
MenC rSBA titres. Titres <4 (the lower limit of detection of 
the assay) were given an arbitrary value of 2 to be able to 
log10 transform these values to conduct the analysis. 
Non-inferiority was met if the lower 95% confidence limit 
of the difference in the mean log10 MenC rSBA between 
the single infant dose MenC-CRM group minus the two 
infant dose MenC group was >−0.35 (equivalent to a 
non-inferiority margin of >−10%) at one month after Hib-
MenC-TT vaccination. This margin was derived from pub-
lished data measured one month after a MenAC 
polysaccharide vaccine challenge was administered to 
infants aged 12 months who had been primed with 
MenC-TT at 2 and 4 months of age.11 Based on this margin 
of −0.35, with at least 160 participants enrolled in each of 
the single infant dose MenC-CRM and two infant dose 
MenC-CRM groups, the power to show the primary objec-
tive at 2.5% one sided level of significance was 90% 
(allowing for a 12.5% dropout rate). Sample size calcula-
tions for the additional two arms of the study resulted in 
an unusual 10:10:7:4 allocation ratio. Details of all calcu-
lations are included in appendix table A. The study design 
was not intended to compare reactogenicity rates between 
the different schedules and so no sample size calculation 
was carried out for these secondary outcomes.
The analysis of the outcome variables was based on 
the intention to treat population. We also performed an 
analysis on the completers population to complement 
the intention to treat population analysis. Participants 
were included in the intention to treat population if 
they had at least one dose and at least one assessment 
after baseline and in the completers population if they 
received all vaccine doses and had all planned assess-
ments. Models used in the analyses contained the terms 
dose group (four levels) and study centre (five levels).
We performed analysis of variance (ANOVA) of the 
log10 transformed rSBA titres at each blood sampling visit 
and present results as geometric mean titres with 95% 
confidence intervals. Binary variables were analysed 
with logistic regression with results of a comparison 
between two levels of a factor reported as odds ratios 
(95% confidence interval). P<0.05 was considered signif-
icant. We used STATA 13 and StatXact 9 for the immuno-
genicity analyses and SAS v9.3 for the safety analyses.
results
Out of the 509 infants enrolled in the study, 497 com-
pleted the primary immunisation phase, 478 the booster 
phase, and 453 the persistence phase (fig 1).
Demography
The mean age of the participants at enrolment (n=509) 
was 8.5 weeks (range 6.9–10.6), 51.7% (263) were boys, 
and 90.2% were white. At the booster and persistence 
phases the mean age of the infants was 12.5 months 
(11.9–13.6) and 24.1 months (22.1–27.3), respectively.
immunogenicity
Although we planned to adjust for study centre, adjust-
ment made no difference to the primary analysis or to 
any of the secondary analyses. All results presented are 
unadjusted.
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Primary objective
Our primary objective was met as the immunogenicity of 
one priming dose of MenC-CRM at 3 months was non- 
inferior (and in fact was superior) to two MenC-CRM 
doses given at 3 and 4 months of age, when assessed at 
13 months of age after the Hib-MenC-TT booster. One 
month after administration of the Hib-MenC-TT vaccine 
at 12 months of age, participants in the single infant 
dose and two infant dose MenC-CRM groups had MenC 
rSBA geometric mean titres of 660 (95% confidence 
interval 498 to 876) and 295 (220 to 398), respectively (fig 2 
and appendix table B). These corresponded to a differ-
ence of 0.35 (0.17 to 0.53) in the mean log10 MenC rSBA 
between the single infant dose and two infant dose 
MenC-CRM groups. Therefore, as the lower 95% confi-
dence limit was >−0.35 (that is, greater than the equiva-
lent non-inferiority margin of −10%), the primary 
objective of the study was met. The immunogenicity of 
the Hib-MenC-TT vaccine after the single infant dose 
MenC-CRM schedule was actually superior to the immu-
nogenicity of the two dose MenC-CRM infant priming 
regimen as shown by the 95% confidence intervals of the 
difference, which did not cross 0.
Primary immunisation phase
At 5 months of age two MenC-CRM doses resulted in a 
significantly higher proportion of infants with MenC 
rSBA ≥1:8 (100% v 84%, P<0.001) and ≥1:128 (99.3% v 
48.6%; P<0.001) (table 2) as well as higher MenC rSBA 
geometric mean titres (620.5 v 53.6; P<0.001) compared 
with a single MenC-CRM dose (fig 2 and appendix table 
B). Similarly, the percentage of vaccinated infants with 
MenC rSBA above the thresholds of protection after a 
two dose MenC-CRM priming schedule was higher com-
pared with one priming dose of MenC-TT (100% v 93.9% 
(P=0.004) with MenC rSBA ≥1:8 and 99.3% v 79.8% 
(P<0.001) with MenC rSBA ≥1:128, respectively); an 
observation that was also reflected in higher MenC rSBA 
geometric mean titres (620.5 v 169.4; P<0.001). A com-
parison of the immunogenicity of single doses of the 
different MenC glycoconjugates showed that priming 
with one dose of the MenC-TT vaccine resulted in a 
higher percentage of infants with MenC rSBA above the 
predefined cut off for protection and induced higher 
MenC rSBA geometric mean titres than a single MenC-
CRM dose (93.9% v 84.0% (P=0.018) with MenC 
rSBA≥1:8 and MenC rSBA geometric mean titres of 169.4 
v 53.6 (P<0.001), respectively).
Booster phase
Before Hib-MenC-TT vaccination at 12 months of age, 
waning of the immune response after the different 
MenC vaccine priming schedules was evident, with 
only 26–41% of vaccinated infants still having MenC 
Assessed for eligibility (n=823)
Invited to participate (n=30 746):
Declined (n=1132)       No response (n=28 791)
Randomised (n=509)
Allocated to single infant dose
  MenC-TT group (n=117)
Withdrawn (n=12):
  Withdrew consent (n=4)
  Moved out of area (n=6)
  Lost to follow-up (n=2)
Allocated to control group
  (n=165)
Withdrawn (n=4):
  Withdrew consent (n=4)
Allocated to two infant dose
  MenC-CRM group (n=161)
Withdrawn (n=8):
  Withdrew consent (n=4)
  Moved out of area (n=2)
  Lost to follow-up (n=2)
Allocated to single infant dose
  MenC-CRM group (n=165)
Withdrawn (n=7):
  Withdrew consent (n=4)
  Moved out of area (n=2)
  Lost to follow-up (n=1)
ITT analysis
booster phase*
Eligible (n=105):
  Nil serum (n=21)
  Analysed (n=84)
Eligible (n=62):
  Nil serum (n=8)
  Analysed (n=54)
Eligible (n=153):
  Nil serum (n=27)
  Analysed (n=126)
Eligible (n=158):
  Nil serum (n=22)
  Analysed (n=136)
Eligible (n=102):
  Nil serum (n=7)
  Analysed (n=95)
Eligible (n=57):
  Nil serum (n=2)
  Analysed (n=55)
Eligible (n=144):
  Nil serum (n=17)
  Analysed (n=127)
Eligible (n=150):
  Nil serum (n=14)
  Analysed (n=136)
ITT analysis
persistence
phase†
Withdrawn (n=3):
  Moved out of area (n=2)
  Lost to follow-up (n=1)
Withdrawn (n=5):
  Withdrew consent (n=3)
  Moved out of area (n=2)
Withdrawn (n=9):
  Withdrew consent (n=4)
  Moved out of area (n=3)
  Lost to follow-up (n=2)
Withdrawn (n=8):
  Withdrew consent (n=2)
  Moved out of area (n=4)
  Lost to follow-up (n=2)
Excluded (n=314):
  Not meeting inclusion criteria (n=158)
  Declined to participate (n=156)
* 1 month aer Hib-MenC-TT vaccination at 12 months of age
† 12 months aer Hib-MenC-TT vaccination
Fig 1 | MenC vaccination schedules and flow of infants in intention to treat population
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rSBA ≥1:8. MenC rSBA geometric mean titres decreased 
77-fold, 12.8-fold, and 18.2-fold after infant vaccination 
with two MenC-CRM doses, a single MenC-CRM dose, or 
a single MenC-TT dose, respectively (fig 2 and appendix 
table B). Although the two infant dose MenC-CRM prim-
ing schedule resulted in a significantly higher percent-
age of infants with MenC rSBA ≥1:8 (but not with MenC 
rSBA ≥1:128) compared with a single infant dose MenC-
CRM schedule, we saw no significant differences com-
pared with the single infant dose MenC-TT schedule. 
For recipients of the MenC-TT vaccine in infancy, the 
proportion with MenC rSBA above the threshold for pro-
tection as well as the MenC rSBA geometric mean titres 
were higher than a single MenC-CRM infant priming 
dose (39.8% v 25.9% (P=0.023) with MenC rSBA ≥1:8, 
and MenC rSBA geometric mean titres of 9.3 v 4.4, 
P<0.002).
One month after Hib-MenC-TT vaccination at 12 
months of age there was no difference in the percentage 
of infants with MenC rSBA ≥1:8 after a single MenC-CRM 
or MenC-TT infant priming dose compared with two 
MenC-CRM infant priming doses (97.1% and 100% v 
92.1%, respectively), although all three schedules 
resulted in significantly higher rates of seroprotection 
against MenC compared with those who were not 
primed in infancy (table 2). The percentage of vacci-
nated infants with MenC rSBA ≥1:128, however, was sig-
nificantly higher after single dose MenC-CRM/TT infant 
priming compared with two MenC-CRM infant doses or 
no priming at all (91.9% and 98.8% v 81.0% and 68.5%, 
respectively), which was also reflected in significantly 
higher MenC rSBA geometric mean titres between these 
groups (fig 2 and appendix table B). Although after the 
Hib-MenC-TT boost we saw no significant differences in 
the percentage of infants with MenC rSBA ≥1:8 between 
a single infant priming dose of MenC-CRM and 
MenC-TT, the percentage of infants with MenC rSBA 
≥1:128 (table 2) as well as the MenC rSBA geometric 
mean titres were significantly higher in those who had 
been primed with MenC-TT (fig 2).
Persistence phase
Twelve months after Hib-MenC-TT vaccination, only 
19.7%, 30.9%, and 27.3% of those who had been primed 
with two MenC-CRM doses, one MenC-CRM dose, or 
who had not been primed at all in infancy, respectively, 
still had MenC rSBA ≥1:8. We found no significant differ-
ences in the percentage of infants with MenC rSBA≥1:8 
or in MenC rSBA geometric mean titres between the sin-
gle or two infant dose MenC-CRM groups compared 
with the control group, though significantly more par-
ticipants who were primed with one MenC-CRM dose in 
infancy had MenC rSBA ≥1:8 compared with those who 
received two MenC-CRM infant priming doses (table 2), 
a finding that was not reflected in significant differ-
ences between the MenC rSBA geometric mean titres 
persisting in the participants within the MenC-CRM 
primed groups (fig 2 and appendix table B). In contrast, 
82.1% of children who were primed with one MenC-TT 
dose in infancy had MenC rSBA ≥1:8 and 69.5% had 
MenC rSBA ≥1:128; values that were significantly higher 
than those persisting after all other schedules (table 2). 
In addition, although the MenC rSBA geometric mean 
titres persisting after a single dose MenC-TT priming 
and Hib-MenC-TT boosting schedule had declined over 
12 months, they were still significantly much higher 
than after all the other schedules (fig 2 and appendix 
table B).
safety
Primary vaccination phase
There were no significant differences in the frequency of 
local adverse events at 3 months of age between any of 
the MenC priming schedules (all 95% confidence inter-
vals for the odds ratios for group comparisons included 
1.0), with local pain, erythema, swelling, and induration 
being reported in each of the MenC groups, excluding 
Blood sampling visit*
M
en
C 
rS
B
A 
ti
tr
e
5 month 12 month 13 month 24 month
2
4
8
16
32
128
256
512
64
2048
4096
1024
MenC-CRM Two MenC-CRM Control MenC-TT
*5 month visit: 28-42 days aer last vaccinations administered at 4 months of 
age; 12 month visit: at 51-58 weeks of age; 13 month visit: 28-42 days aer 
Hib-MenC-TT vaccination at 51-58 weeks of age; 24 month visit: 11-12 months 
aer Hib-MenC-TT vaccination
Fig 2 | geometric mean titres (and 95% confidence interval) 
for meningococcal C (MenC) rabbit serum bactericidal 
antibody (rsba) at visits performed at age 5, 12, 13, and 24 
months according to type of MenC priming schedule 
(intention to treat population)
table 2 | Percentage of participants with meningococcal C (MenC) rabbit serum bactericidal antibody (rsba) ≥1:8 and ≥1:128 thresholds of protection 
(itt population) after vaccination with MenC-cross reacting material 197 (MenC-CrM) or MenC-tetanus toxoid (MenC-tt) conjugate formulations
study group MenC rsba ≥1:8 (95% Ci)* by age (months) MenC rsba ≥1:128 (95% Ci)* by age (months)
5 12 13 24 5 12 13 24
Single infant dose menC-CRm group 84 (77 to 90) 26 (19 to 34) 97 (93 to 99) 31 (23 to 39) 49 (40 to 57) 7 (3 to 12) 92 (86 to 96) 11 (6 to 18)
Two infant dose menC-CRm group 100 (97 to 100) 41 (33 to 50) 97 (92 to 99) 20 (13 to 28) 99 (96 to 100) 13 (7 to 20) 81 (73 to 87) 6 (2 to 11)
Control group 2 (0 to 10)† 0 83 (71 to 92) 27 (16 to 41) 2 (0 to 10)† 0 69 (54 to 80) 11 (4 to 22)
Single infant dose menC-TT group 94 (87 to 98) 40 (30 to 50) 100 (96 to 100) 82 (73 to 89) 80 (71 to 87) 23 (15 to 32) 99 (94 to 100) 69 (59 to 79)
*Presented numbers have been rounded up; accurate numbers are presented within text. 
†One participant in control group was found to have menC rSbA titre of 1:128 at 5 month blood sampling visit that was then undetectable at 12 month visit. This was likely from transplacentally 
acquired maternal antibody.
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the control group, in up to 22%, 45%, 16%, and 25% of 
infants, respectively (appendix table C). Similarly we 
found no significant differences when we compared the 
frequency of systemic adverse events, with the most fre-
quently reported symptoms being increased sleepiness 
in up to 50% and irritability in up to 66% of infants in 
each group (appendix table C). Fever ≥38°C was reported 
in ≤1% in each group. One participant in the two infant 
dose MenC-CRM group was admitted to hospital because 
of a vaccine related serious adverse event consisting of a 
haematoma at the site of the first MenC vaccine. This 
infant was subsequently diagnosed with factor VIII defi-
ciency and made a complete recovery but was with-
drawn from the study.
booster phase
The priming regimen before Hib-MenC-TT vaccine 
administration at 12 months of age did not result in any 
observable significant differences in the frequency of 
local adverse events between any of the groups (all 95% 
confidence intervals for the odds ratios for group com-
parisons included 1.0), with up to 29% having pain, 
76% erythema, 23% swelling, and 31% experiencing 
induration at the Hib-MenC-TT injection site in each 
group. Similarly, differences in the expected systemic 
adverse events between the groups were not significant, 
with drowsiness, irritability, and diminished appetite 
being the most commonly reported side effects in up to 
39%, 61%, and 35%, respectively, in each group (appen-
dix table C). Fever was the least frequent systemic 
adverse event, occurring in 10% of participants in each 
group. No vaccine related serious adverse events 
occurred in the booster phase.
discussion
The number of MenC doses used in the current vaccina-
tion schedules in different countries within Europe, as 
well as internationally, varies from none to one or two 
infant priming doses followed by another dose in the 
second year of life, with or without a further boost in 
adolescence (table 3).15–19 This randomised controlled 
study provides data directly supporting a reduction in 
the routine MenC immunisation schedule from two 
infant doses to a single infant dose prime plus booster: 
a change that has been implemented in the UK since 
June 2013.8
MenC vaccine efficacy data have shown that MenC 
rSBA titres ≥1:8, and more conservatively ≥1:128, are 
correlated with protection against MenC disease on a 
population level.14 Priming with two MenC-CRM doses 
at 3 and 4 months of age does not offer any advantage 
over priming with a single MenC-CRM or MenC-TT dose 
at 3 months of age because MenC antibodies wane 
below these thresholds for most infants in all three 
groups, and at least 97% of children had MenC rSBA 
≥1:8 after a Hib-MenC-TT boost at 12 months of age, 
irrespective of the number of MenC doses used for 
infant priming. Our findings are similar to those 
reported in another study, which showed that 98% of 
infants had MenC rSBA ≥1:8 in response to a 12 month 
Hib-MenC-TT booster dose after one MenC infant prim-
ing dose.12 That study, however, made no comparison 
with the response to a two dose MenC infant priming 
schedule or a control group.
Intriguingly, priming with a single MenC-CRM dose 
induced higher post-Hib-MenC-TT rSBA geometric 
mean titres than two priming doses, suggesting that 
the administration of a greater amount of MenC anti-
gen during priming reduces the subsequent immune 
response to the 12 month MenC conjugate vaccine 
booster dose. The underlying mechanism, which is not 
reflected in the frequencies of MenC-specific memory B 
cells in peripheral blood detected at 5, 12, or 13 
months,20 could still be related to differences in num-
bers of memory B cells if the pool is considered to be 
resident in lymphoid tissues and therefore inaccessible 
with peripheral blood sampling. Furthermore, this phe-
nomenon might be the result of dose dependent differ-
ences in carrier protein that manifest when different 
table 3 | Current international infant meningococcal C (MenC) vaccination schedules
Country and region
no of doses  
(before age <2 
years)
recommended age of vaccination
adolescent 
vaccination<12 months 12–24 months
america (north)
Canada15:
 manitoba 1 — 12 months Yes
 New brunswick 1 — 12 months Yes*
  Newfoundland and 
Labrador
1 — 12 months Yes*
 Quebec 1 — 12 months Yes
 Nova Scotia 1 — 12 months Yes
 Nunavut 1 — 12 months Yes* (if no 
previous dose)
 Ontario 1 — 12 months Yes*
 Prince Edward Island 1 — 12 months Yes*
 Saskatchewan 1 — 12 months Yes*
 british Columbia 2 2 months 12 months Yes
 Northwest Territories 2 2 months 12 months Yes†
 Yukon 2 2 months 12 months Yes
 Alberta 3 2, 4 months 12 months Yes*
USA16 Nil‡ — — Yes*
america (south)
brazil17 3 3, 5 months 15 months No
australia18
Whole country 1 — 12 months* No
europe19
Austria 1 — 12–14 months Yes*
belgium 1 — 15 months No
Cyprus 1 — 12–13 months No
France 1 — 12–23 months No
Germany 1 — 11–23 months No
Italy 1 — 13–15 months No
Netherlands 1 — 14 months No
Portugal 1 — 12 months No
Iceland 2 6, 8 months — No
Spain 2 2 months 12 months Yes
UK 2 3 months 12–13 months§ Yes
Greece 3 2, 4 months 6 months-5 years Yes*
Ireland 3 4, 6 months 13 months No
*Given as conjugate menACWY vaccine.
†In Northwest Territories menACWY conjugate vaccine is administered to post-secondary school students 
attending schools outside territory.
‡Four dose series of Hib-menCY-TT or menACWY-CRm at 2, 4, 6, and 12–15 months only in children at increased 
risk of meningococcal disease.
§Hib-menC-TT.
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MenC glycoconjugate vaccine formulations are used for 
priming and boosting. A similar effect has also been 
observed in children challenged with a MenC pure 
polysaccharide formulation after infant priming with 
one dose of MenC-TT, which induced significantly 
higher post-boost MenC rSBA geometric mean titres 
than two dose MenC-TT infant priming.11 The relatively 
reduced post-booster response seen with an increase in 
the number of priming doses of MenC conjugate vac-
cine is not the same as the hyporesponsiveness that 
occurs in children repeatedly vaccinated with a pure 
polysaccharide MenC vaccine compared with others 
who are being vaccinated with the same MenC polysac-
charide formulation for the first time.21 The latter is 
thought to result from the terminal differentiation of B 
cells into plasma cells without the formation of mem-
ory B cells, which is induced by repeated immunisation 
with a T cell independent antigen that, as a net result, 
depletes the MenC specific B cell pool.22
Two months after infant vaccination, one MenC-TT 
dose was significantly more immunogenic than one 
dose of MenC-CRM (fig 2 and table 2); and after a 
 Hib-MenC-TT boost at 12 months of age, the MenC rSBA 
geometric mean titres were significantly higher in those 
primed with MenC-TT than all other study groups (fig 2 
and appendix table B). Such differences in immunoge-
nicity are known to persist after a MenC boost in the 
second year of life, irrespective of whether MenC-TT or 
MenC-CRM are used for boosting.23 Furthermore, at 2 
years of age 82% of vaccinated children primed with 
MenC-TT, whose MenC rSBA geometric mean titres were 
significantly higher than the MenC rSBA geometric 
mean titres measured in those primed with a MenC-
CRM schedule and in those who were not primed at all, 
still had MenC rSBA ≥1:8 in contrast with ≤30% of those 
primed with other MenC schedules. Despite evidence of 
immune memory after MenC disease and vaccination,24 
the antibody response after MenC exposure is not rapid 
enough to prevent disease in those with a MenC rSBA 
titre <1:8,7 showing the importance of generating high 
rSBA geometric mean titres after booster, leading to a 
higher proportion of children maintaining rSBA titres 
above the 1:8 threshold through early childhood.
Such results are assumed to indicate differences in 
immunogenicity of the vaccines that relate to the T cell 
help induced by the different carrier proteins, though 
there are other manufacturing differences between 
MenC-TT and MenC-CRM that make it difficult to for-
mally draw this conclusion. Differences in the per-
sistence of post-boost MenC bactericidal antibody are 
consistent with observations from other studies of the 
persistence of MenC bactericidal antibody after priming 
with different MenC glycoconjugates in infancy.25 26 Our 
findings show that it would be more rational to prime 
infants with MenC-TT, rather than MenC-CRM, and 
boost with Hib-MenC-TT.
The proportions of infants with a MenC rSBA titre ≥1:8 
after immunisation with a single dose of Hib-MenC-TT at 
12 months of age, without infant priming, reached up to 
83%; a proportion that might be acceptable in countries 
where MenC disease is currently under control. The 
introduction of just a single dose of MenC vaccine at 12 
months of age might not be appropriate in other coun-
tries where herd immunity has not been established 
through the initiation of the programme with a “catch 
up campaign” and subsequent adolescent boosting 
(used to maintain herd immunity). A routine 12 month 
only MenC immunisation programme, in the absence of 
such herd immunity, would leave unvaccinated infants 
as well as vaccinated children, whose immunity has 
waned over time, at risk. The low titres of bactericidal 
antibodies in infancy and from 2 years of age onwards 
observed with just a single MenC vaccination at 12 
months of age suggest prevention of breakthrough cases 
in infants and preschool children depend on herd 
immunity induced by a catch up vaccination campaign 
that could then be sustained through adolescent boost-
ing. A single MenC toddler dose was successful in con-
trolling MenC disease in the Netherlands,27 Australia,28 
and Canada,29 where infants were protected through 
herd protection induced by an initial catch up campaign 
targeting older children and adolescents. An alternative, 
as in the US, is to provide the first MenC dose in adoles-
cence.30 A MenC priming dose at 12 months of age, how-
ever, might still be important for a robust anamnestic 
response after a MenC boost in adolescence.31 Indeed if 
herd immunity in the UK is maintained through a robust 
adolescent MenC booster programme, the 3 month 
infant MenC vaccine might conceivably be dropped from 
the vaccination programme without any change in the 
current excellent population protection. Furthermore, 
the anticipated introduction of a routine MenB vaccina-
tion schedule in infancy, with a MenB vaccine that con-
tains relatively well conserved meningococcal 
subcapsular proteins that might also be common among 
different meningococcal strains independent of the cap-
sular polysaccharide type,32 is predicted to protect 
against other serogroups, including some clones of 
MenC, in the first 12 months of life, potentially support-
ing the removal of the infant MenC doses.
strengths and limitations
The inclusion of a control group in this study made it 
possible to compare the post-boost immunogenicity of 
the different MenC priming schedules with that induced 
by administration of the first MenC conjugate vaccine 
dose in MenC vaccine naive participants at 12 months of 
age. Follow-up of bactericidal antibody up to 24 months 
of age helped us to investigate if differences in immuno-
genicity between the different infant MenC priming 
schedules are long lasting: an effect that impacts plan-
ning of MenC immunisation programmes. We did not 
look at the differences in antibody that could have been 
induced by boosting the different MenC-CRM priming 
schedules with a MenC-CRM booster dose because only 
Hib-MenC-TT is currently being used as a booster dose in 
the second year of life in the UK. Future studies looking 
at the persistence of bactericidal antibodies in children 
older than 2 years would show if the differences seen 
between the MenC-TT and MenC-CRM priming sched-
ules or the control group are sustained. The response to 
a MenC boost in adolescents previously primed with a 
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single MenC dose at 12 months of age compared with 
age matched MenC naive controls also merits further 
investigation.
The lack of significant differences in the local adverse 
events at the MenC injection site at 3 months as well as 
at the Hib-MenC-TT site at 12 months of age, and in the 
corresponding systemic adverse events, between the 
different schedules could possibly have resulted from 
our study being underpowered to detect differences in 
reactogenicity between the groups. Such differences 
could be investigated in a larger study.
Conclusions
In countries where the incidence of invasive MenC dis-
ease in infancy has been controlled or practically elim-
inated after a routine MenC vaccination programme, 
two MenC infant priming doses could be reduced to a 
single priming dose without loss of immediate post-
booster immunogenicity and without any effect on 
reactogenicity. Unlike MenC-TT, priming with MenC-
CRM or administering the first MenC dose at the age of 
12 months does not result in bactericidal antibody that 
is sustained at 24 months of age above the accepted 
protective threshold for most young children. Imple-
mentation of MenC vaccine prime and boost schedules 
with MenC tetanus toxoid conjugates seems more likely 
to induce sustained protection against MenC disease in 
early childhood. In the absence of any infant MenC vac-
cine priming doses, the protection provided by just one 
MenC vaccine dose administered at 12 months of age 
would strongly rely on the persistence of herd protec-
tion, induced by a previous catch up MenC immunisa-
tion campaign, which could then be maintained by a 
booster in adolescence.
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